improving solubility

Poor solubility is an obvious barrier to advancing potentially efficacious drug candidates. In this interview Jennifer Sheng, Fellow at Novartis, discusses the most efficient approaches for...

In preparation for the 8th Annual Improving Solubility Summit, taking place in June, Pharma IQ would like to invite you to take part in a short survey. The survey consists of no more than 8 questions...

Solving solubility problems is one of the leading challenges in drug development, as poorly soluble compounds are estimated to account for 60% of compounds. Preclinical development encompasses the a...

Current estimates indicate that 40% of drugs on the market place and 90% of APIs in development are poorly soluble. David Elder, Externalisation Director for GlaxoSmithKline and Pharma IQ Advisory B...

Lipid formulations have gained momentum in recent years as an efficient means for improving solubility of new chemical entities, but ensuring the stability of these systems can prove challenging. Dr...

One aspect of solubility which continues to get much attention is nanotechnology. The concept sees pharmaceutical firms work on a molecular scale in an effort to engineer the best possible formula...

Ameet Ambarkhane, Principal Scientist at Novartis, joins Pharma IQ to discuss harnessing the potential of nanotechnology to aid in the delivery of poorly soluble compounds and bottlenecks in early d...

With the advent of improved techniques for drug discovery, there has been a transition towards new chemical entities to be hydrophobic and non-polar, which in turn has made solubilization of these e...